TY - JOUR
T1 - Hematopoietic cell transplantation for acute lymphoblastic leukemia
T2 - review of current indications and outcomes
AU - Khazal, Sajad
AU - Kebriaei, Partow
N1 - Funding Information:
Editorial support was provided by Bryan Tutt, Scientific Editor, Research Medical Library.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The treatment landscape for patients with acute lymphoblastic leukemia (ALL) is changing. Continued investigation into the biology of ALL, and broader use and more precise methods of measuring residual disease allow for improved risk stratification of patients and identification of the subset of patients at greatest risk of disease relapse and who may benefit from hematopoietic cell transplantation (HCT) in first complete remission. Further, recent advances in HCT preparative regimens, donor selection, graft manipulation, and graft-versus-host disease prophylaxis and treatment have resulted in fewer transplant-related morbidities and mortality and better survival outcomes. Finally, the development of effective immunotherapeutic salvage agents, such as the chimeric antigen receptor T-cell therapy, tisagenlecleucel, have significantly changed the treatment landscape of this disease, allowing patients with advanced disease to be considered for HCT with curative intent. In this review, we will provide an update on the indications and outcome of pediatric and adult ALL.
AB - The treatment landscape for patients with acute lymphoblastic leukemia (ALL) is changing. Continued investigation into the biology of ALL, and broader use and more precise methods of measuring residual disease allow for improved risk stratification of patients and identification of the subset of patients at greatest risk of disease relapse and who may benefit from hematopoietic cell transplantation (HCT) in first complete remission. Further, recent advances in HCT preparative regimens, donor selection, graft manipulation, and graft-versus-host disease prophylaxis and treatment have resulted in fewer transplant-related morbidities and mortality and better survival outcomes. Finally, the development of effective immunotherapeutic salvage agents, such as the chimeric antigen receptor T-cell therapy, tisagenlecleucel, have significantly changed the treatment landscape of this disease, allowing patients with advanced disease to be considered for HCT with curative intent. In this review, we will provide an update on the indications and outcome of pediatric and adult ALL.
KW - Acute lymphoblastic leukemia
KW - hematopoietic cell transplantation
KW - indications
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=85107503340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107503340&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1933475
DO - 10.1080/10428194.2021.1933475
M3 - Review article
C2 - 34080951
AN - SCOPUS:85107503340
SN - 1042-8194
VL - 62
SP - 2831
EP - 2844
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -